Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity.
Simvastatin, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) is known to stimulate apoptotic cell death and induce cell cycle arrest through inhibition of proteasome. The purpose of this study is to investigate whether simvastatin would be synergistic with irinotecan against human non-small cell lung cancer (NSCLC) cells. Antitumor effect was measured by growth inhibition of cells and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The cytotoxic interaction between irinotecan and simvastatin was assessed using the combination index. Effects on cell cycle distribution and apoptosis were determined by flow cytometry and DNA fragmentation. Proteasome activity was measured by ELISA quantification of 20S proteasome. NF-κB activation was determined using TransAM™ NF-κB p65 Transcription Factor Assay Kit. IκB-α was measured by immunoblot. A combination of irinotecan with simvastatin showed significantly enhanced cell growth inhibition compared with irinotecan alone, which resulted in a synergistic cytotoxicity. Irinotecan and simvastatin combination treatment of A549 and H460 cells increased G(1) phase arrest, which was associated with up-regulation of p21(WAF1/CIP) and p53 compared with irinotecan alone. In addition, simvastatin combination treatment increased irinotecan-related apoptosis as determined by fluorescence microscopy and flow cytometric analysis. We also found that combination therapy showed superior proteasome inhibitory activity leading to effectively suppress NF-κB transcription factor activation. Consistently, this effect was associated with up-regulation of IκB-α. These findings suggest that simvastatin enhances irinotecan-induced apoptosis in human NSCLC cells through inhibition of proteasome activity.
Park
In Hae
IH
Lung Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Kim
Jin Young
JY
Choi
Ji Young
JY
Han
Ji-Youn
JY
D017209:Apoptosis / Q000187:drug effects*; D001562:Benzimidazoles / Q000378:metabolism; D015153:Blotting, Western; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000494:pharmacology; D002289:Carcinoma, Non-Small-Cell Lung / Q000201:enzymology / Q000473:pathology*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D005434:Flow Cytometry; D006801:Humans; D020672:I-kappa B Proteins / Q000378:metabolism; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000201:enzymology / Q000473:pathology*; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000378:metabolism; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D061988:Proteasome Inhibitors; D019821:Simvastatin / Q000494:pharmacology*; D013194:Staining and Labeling; D013379:Substrate Specificity / Q000187:drug effects
D001562:Benzimidazoles; D020672:I-kappa B Proteins; D016328:NF-kappa B; C000606204:NFKBIA protein, human; D061988:Proteasome Inhibitors; D000072000:NF-KappaB Inhibitor alpha; D000077146:Irinotecan; D019821:Simvastatin; D046988:Proteasome Endopeptidase Complex; C017807:bisbenzimide ethoxide trihydrochloride; D002166:Camptothecin
Eur J Haematol. 2007 Sep;79(3):240-3
17655704
Clin Cancer Res. 2002 Mar;8(3):641-61
11895891
Oncologist. 2001;6(1):66-80
11161230
Oncogene. 1998 Nov 5;17(18):2393-402
9811471
Clin Cancer Res. 2008 Mar 15;14(6):1649-57
18347166
J Natl Cancer Inst. 2006 Dec 20;98(24):1819-25
17179483
Leukemia. 2002 Apr;16(4):508-19
11960327
J Biol Chem. 2000 Mar 31;275(13):9501-9
10734098
J Natl Cancer Inst. 2007 Jan 3;99(1):32-40
17202111
Clin Cancer Res. 2005 Mar 15;11(6):2398-407
15788691
Nature. 1990 Feb 1;343(6257):425-30
1967820
J Biol Chem. 1999 Jul 30;274(31):21926-31
10419514
Science. 2001 May 11;292(5519):1160-4
11349148
J Immunol. 2007 Feb 15;178(4):2507-16
17277159
Nat Rev Cancer. 2005 Dec;5(12):930-42
16341084
Cancer Sci. 2004 May;95(5):464-8
15132777
Cancer Cell. 2004 May;5(5):417-21
15144949
Cancer. 2006 Dec 1;107(11):2688-97
17075878
Nat Med. 1999 Apr;5(4):412-7
10202930
Biochem Pharmacol. 2008 Feb 15;75(4):907-13
18036510
N Engl J Med. 2003 Jun 26;348(26):2597-8
12826633
Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):7797-802
10393901
N Engl J Med. 2006 Dec 21;355(25):2705-7
17183004
Oncogene. 2005 May 26;24(23):3786-96
15782134
J Natl Cancer Inst. 1994 Oct 19;86(20):1517-24
7932806